Nippon India Pharma Bonus Bonus Growth Direct Plan
SIP amount
Temporarily restricted by fund house
Lumpsum amount
Temporarily restricted by fund house

Nippon India Pharma Bonus Bonus Growth Direct Plan

NAV
₹318.1032
+0.48%
(30 Nov)
AUM
4,786 Cr
TER
1.05%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+17.3%
+17.3%
+17.3%
+17.3%
-3.2%
3Y
+40.1%
+40.1%
+39.5%
+39.5%
+25.4%
5Y
+22.1%
+22.1%
NA
NA
+17.4%
ALL
+17.6%
+17.6%
+39.2%
+39.2%
+16.5%
VOL
20.4%
20.4%
28.2%
28.2%
16.4%
TER
0.6%
0.6%
1.1%
1.1%
1.1%
AUM
₹778 Cr
₹778 Cr
₹733 Cr
₹733 Cr
₹4,786 Cr
INFO
0.86
0.86
1.39
1.39
1.01
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Nippon India Pharma Bonus Bonus (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Oct
Top holdings
Sun Pharmaceuticals Industries Ltd
14.9%
Cipla Ltd
9.0%
Dr Reddy's Laboratories Ltd
8.2%
Lupin Ltd
6.6%
Abbott India Ltd
5.2%
Torrent Pharmaceuticals Ltd
5.1%
Narayana Hrudayalaya Ltd
5.0%
Divi's Laboratories Ltd
4.9%
Apollo Hospitals Enterprise Ltd
4.0%
Aurobindo Pharma Ltd
3.9%
Top industry exposure
Healthcare
97.9%
Other information
Minimum SIP
Restricted (AMC)
Minimum lumpsum
Restricted (AMC)
Additional lumpsum
Restricted (AMC)
Portfolio turnover
24%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.
Fund manager(s)
Sailesh Raj Bhan
Kinjal Desai

FAQs